Novo Nordisk Investing Activities - Other 2010-2025 | NVO
Novo Nordisk annual/quarterly investing activities - other history and growth rate from 2010 to 2025. Investing activities - other can be defined as the net amount of items a company reports that are too small to report separately. Additionally, this field holds the sum of items a company reports that cannot be assigned to any other standardized field in the investing activities section of the Cash Flows Statement
- Novo Nordisk investing activities - other for the quarter ending March 31, 2025 was $0M, a 0% increase year-over-year.
- Novo Nordisk investing activities - other for the twelve months ending March 31, 2025 was $0M, a 0% increase year-over-year.
- Novo Nordisk annual investing activities - other for 2024 was $0B, a 0% decline from 2023.
- Novo Nordisk annual investing activities - other for 2023 was $0B, a 0% decline from 2022.
- Novo Nordisk annual investing activities - other for 2022 was $0B, a 100% decline from 2021.
Novo Nordisk Annual Investing Activities - Other
(Millions of US $) |
| 2024 |
$N/A |
| 2023 |
$N/A |
| 2022 |
$N/A |
| 2021 |
$1 |
| 2020 |
$3 |
| 2019 |
$3 |
| 2018 |
$3 |
| 2017 |
$4 |
| 2016 |
$4 |
| 2015 |
$N/A |
| 2014 |
$N/A |
| 2013 |
$N/A |
| 2012 |
$N/A |
| 2011 |
$-48 |
| 2010 |
$-91 |
| 2009 |
$-78 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$306.050B |
$42.122B |
|
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
|
